Skip to main content

Boehringer Ingelheim – Schizophrenia



The study is looking to prevent patients with Schizophrenia from becoming worse or relapsing over a 6 month time period.

Sponsors: Boehringer Ingelheim

Phase : 2

Indication: Schizophrenia

Age: 18 years to 55 years

Category: Treatment


For more information please visit



Studies Currently Available At

Sign Up For This Study